Alcohol-associated liver disease (ALD) is driven by oxidative stress, inflammation, hepatocyte death, and intestinal barrier disruption, yet targeted pharmacological options remain limited. Here, we investigated LB23, a proteolysis-targeting chimera designed to degrade poly (ADP-ribose) polymerase 1 (PARP1), in cellula...
Qian-Yuan Gong, Jian-Yu Liu, Hua-Cui Li et al.· Biochemical Pharmacology· 0 citations
The findings support further investigation of BET/BRD4-associated pharmacological strategies in ESCC, while target-specific validation and expanded in vivo mechanistic and safety studies remain warranted.
Chun-Lan Pu, Jian-Yu Liu, Heng-Rui Fan et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.